Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Pharmaceutical Poisoning: Potential Scenarios01:26

Pharmaceutical Poisoning: Potential Scenarios

Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prescription - Dermatology and Wound Care.

International journal of pharmaceutical compounding·2024
Same author

Prescription: Technology in Compounding.

International journal of pharmaceutical compounding·2024
Same author

Pharmaceutical Waters Used in Sterile and Nonsterile Compounding.

International journal of pharmaceutical compounding·2024
Same author

Quality Control: Water Activity Considerations for Beyond-use Dates.

International journal of pharmaceutical compounding·2024
Same author

Prescription: Pediatric/Geriatric.

International journal of pharmaceutical compounding·2024
Same author

Basics of Compounding: Tips and Hints, Part 4: Lollipops/Lozenges, Gummy Bears, Patches, Flavoring/Coloring, Sweeteners, and Packaging.

International journal of pharmaceutical compounding·2024
Same journal

Compounding and Stability Study of Dipyridamole and Clopidogrel Pediatric Oral Suspensions.

International journal of pharmaceutical compounding·2026
Same journal

Nanoemulsion Reformulation of Nitrosylcobalamin (NO-Cbl) Enhances Solubility, Stability, and Anti-Tumor Potency.

International journal of pharmaceutical compounding·2026
Same journal

Chemical and Microbiological Stability Supporting Extended BUDs in Pentravan® Based Transdermal Preparations.

International journal of pharmaceutical compounding·2026
Same journal

Stability Evaluation of Compounded Benzocaine, Lidocaine, and Tetracaine in VersaPro™ Cream Base.

International journal of pharmaceutical compounding·2026
Same journal

Formulation and In-Vitro Characterization of Gastroretentive Effervescent Floating Tablets of Meloxicam.

International journal of pharmaceutical compounding·2026
Same journal

Ethical and Regulatory Implications of Sourcing Drug X During an FDA-Reported Shortage: 503A vs. 503B Compounding Facilities.

International journal of pharmaceutical compounding·2026
See all related articles

Related Experiment Video

Updated: May 8, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

PostScription: Future Trends in High-Technology Pharmaceutical Compounding

Loyd V Allen1

  • 1International Journal of Pharmaceutical Compounding, Edmond, OK.

International Journal of Pharmaceutical Compounding
|August 28, 2013
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

3D Printing of Preclinical X-ray Computed Tomographic Data Sets
11:06

3D Printing of Preclinical X-ray Computed Tomographic Data Sets

Published on: March 22, 2013

Related Experiment Videos

Last Updated: May 8, 2026

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies
09:30

Microbial Control and Monitoring Strategies for Cleanroom Environments and Cellular Therapies

Published on: March 17, 2023

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform
06:27

Production of Near-Infrared Sensitive, Core-Shell Vaccine Delivery Platform

Published on: October 20, 2020

3D Printing of Preclinical X-ray Computed Tomographic Data Sets
11:06

3D Printing of Preclinical X-ray Computed Tomographic Data Sets

Published on: March 22, 2013